Longhao Zhang

Dr. Longhao Zhang


Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 May 2024 in International Journal of Surgery
Verified
Journal Article
Open access
SWShanshan Wang
Shanshan Wang
YWYunchao Wang
Yunchao Wang
CZChengpei Zhu
Chengpei Zhu
KLKai Liu
Kai Liu
JCJiashuo Chao
Jiashuo Chao
HZHaitao Zhao
Haitao Zhao
Background: The role of conversion surgery in patients with unresectable biliary tract cancer who responded positively to PD-1/PD-L1 inhibitor-based therapy remains unclear. This study aimed to assess the outcomes in patients with or without conversion surgery. Methods: In this cohort study, patients with advanced biliary tract cancer who received combination therapy with PD-1/PD-L1 inhibitors from July 2019 to January 2023 were retrospectively. Patients who exhibited positive responses and met the criteria for conversion surgery were enrolled, and their surgical and oncological outcomes were analyzed. Results: Out of 475 patients, 34 who met the conversion resection criteria were enrolled. The median follow-up was 40.5 months postinitiation of systemic therapy. Ultimately, 13 patients underwent conversion surgery, while 21 received continuation of systemic treatment alone (nonsurgical group). The median interval from the initial antitumor therapy to surgery was 6.7 [interquartile range (IQR) 4.9–9.2] months. Survival with conversion surgery was significantly longer than the nonsurgical cohort, with a median progression-free survival (PFS) [unreached vs. 12.4 months; hazard ratio 0.17 (95% CI: 0.06–0.48); P=0.001] and overall survival (OS) [unreached vs. 22.4 months; hazard ratio 0.28 (95% CI: 0.09–0.84); P=0.02], respectively. After a median postoperative follow-up of 32.2 months in the surgical cohort, eight patients survived without recurrence. The estimated 3-year OS, PFS, and recurrence-free survival rate in the surgical cohort were 59.9, 59.2, and 60.6%, respectively. The R0 resection rate reached 92.3%, with two achieving a pathological complete response. One patient experienced a Clavien–Dindo grade 3 complication without surgery-related mortality. No serious adverse events or surgical delays were observed. Multivariate analysis indicated that conversion surgery was independently associated with OS (P=0.03) and PFS survival (P=0.003). Conclusion: Conversion surgery appears safe and offers survival benefits to patients responding to immune checkpoint inhibitors-based combinations. However, further studies are required to validate this strategy in the era of immunotherapy.

2 July 2025 in American Journal of Gastroenterology
Verified
Journal Article
Open access
KZKai Zhang
Kai Zhang
LZLonghao Zhang
Longhao Zhang
JZJunwei Zhang
Junwei Zhang
XLXin Lu
Xin Lu
HZHaitao Zhao
Haitao Zhao
YXYiyao Xu
Yiyao Xu
An abstract is unavailable. This article is available as a PDF only.

9 January 2026 in American Journal of Gastroenterology
Verified
Journal Article
Open access
JXJingnan Xue
Jingnan Xue
LZLonghao Zhang
Longhao Zhang
NXNanzi Xie
Nanzi Xie
LLLing Lei
Ling Lei
KZKai Zhou
Kai Zhou